Erratum
Year: 2022
Type: erratum
Abstract: In the paper by Suhocki et al. (“Probing gut-brain links in Alzheimer's disease with rifaximin.” Alzheimer's Dement. 2022; 8:e12225. https://doi.org/10.1002/trc2.12225), an error occurred in the preparation of the paper for publication, requiring the following correction. The sentence beginning “All subjects were treated...” in the first paragraph of the Methods section incorrectly gave the rifaximin dose as 500 mg. The sentence should instead read, “All subjects were treated with rifaximin 550 mg twice daily for 3 months.” Additionally, the following text should have been included at the end of the Acknowledgments section: This work was also supported by North Carolina Biotech which had no role in the collection, analysis and interpretation of data, in the writing of the report, or the decision to submit the article for publication. The authors regret these errors.
DOI: 10.1002/trc2.12282
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,200
OpenAlex ID: W4285684910